

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. U 013469-7	SERIAL NO. 09/856,282
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT BONNIE M. DAVIS	
		FILING DATE June 18, 2001	GROUP 1614
OTHER ART (Including Name, Title, Date, Pertinent Dates, Etc.)			
	AA	To follow	
	AB	To follow	
	AC	Tariot P, Gaile SE, Castelli NA, Porsteinsson AP, Treatment of agitation in dementia. New Dir Ment Health Serv 1997; 76: 109-23	
	AD	Devanand DP, Behavioral complications and their treatment in Alzheimer's disease, Geriatrics 1997; 52:Suppl 2:S37-39	
	AE	Jacobsen FM and Comas-Dias L, Donepezil for psychotropic-induced memory loss, J Clin Psychiatry 1999 Oct;60(10):698-704	
	AF	Cummings J L, Mendez MF, Alzheimer's disease: cognitive and behavioral pharmacotherapy. Conn Med 1997; 61:543-552	
	AG	Cummings JL, Changes in neuropsychiatric symptoms as outcome cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl 4:S1-9	
	AH	Cummings JL, Back C, The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6(2Suppl 1):S64-78	
	AI	Schmidt BH, Heinig R, The pharmacological basis for metrifonate's favourable tolerability in the Schmidt BH and Heinig R, ibid.	
	AJ	Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, et al, A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145	
	AK	Cummings J, Winblad B, A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007; 7: 1457-63	
	AL	Witting W, Kwa IH, Eikelenboom P, Mirmiran M, Swaab DF, Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry 1990; 7563-72	
	AM	Tate B, Aboody-Guterman KS, Morris AM, Walcott EC, Majocha RE, Marotta CA, Disruption of.....Proc Natl Acad Sci USA 1992;89:7090-4	
	AN	Mishirna K, Okawa M, Satoh K, Shimizu T, Hozumi S, Hishikawa Y, Different manifestations of circadian Neurobiol Aging 1997; 18:105-9	
	AO	Van Someren EJ, Scherder EJ, Swaab DF, Transcutaneous electrical nerve stimulation (TENS) improves..... Dis Assoc Disord 1998; 12: 114-8	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /JDA/

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.	SERIAL NO.
		U 013469-7	97/856,282
		APPLICANT	
		BONNIE M. DAVIS	
		FILING DATE	GROUP
		June 18, 2001	1614
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)			
To follow	AA	Satlin A, Volicer L, Ross V, Herz L, Campbell S, Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992; 149: 1028-32	
To follow	AB	Satlin A, Volicer L, Stopa EG, Harper D, Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol Aging 1995; 16:765-71	
	AC	Van Someren EJ, Habbebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot AM, disease. Biol Psychiatry 1996; 40:259-70	
To follow	AD	Saito Y, Yamashita I, Yamazaki K, Okada F, Satomi R, Fujieda T, Circadian fluctuation of brain areas. Life Sci 1975; 16:281- 288	
	AE	Reimann D, Gann H, Dressing H, Muller WE, Aldenhoff JB, Influence of the cholinesterase inhibitor sleep. Psychiatry Res 1994; 51:253-267	
To follow	AF	Saito et al. op. cit.	
To follow	AG	Morley BJ, Murrin LC, AF64 depletes hypothalamic high-affinity choline uptake and receptors. Brain Res 1989; 504:238-246	
	AH	Szymusiak R, McGinty D, Fairchild MD, Jenden DJ, Sleep-wake disturbances Brain Res 1993; 629:141-145	
	AI	Tate et al. op. cit.	
To follow	AL	O'Brien CP, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, JG Hardman and LE Limbird, editors in chief, page 560	
To follow	AK	Von der Kammer H, Mayhaus M, Albrecht C, Enderich J, Wegner M, Nitsch RM, Muscarinic factors. J Biol Chem 1998; 273:14538-14544	
	AL	Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C, Differential..... disease, Neuroscience Letters 2001 ; 300: 157-160	
To follow	AM	Blennow, ibid.	
To follow	AN	Nordberg A, Hellstrom-Lindahl E, Almkvist O, Meurling L, Activity of acetylcholinesterase in CSF..... Alzheimer's Reports 1999; 2:347-352	
	AO	Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Fratt RD, et al, Open-label, multicenter, phase 3..... Arch Neurol 2001; 58:427-433	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.	SERIAL NO.
		U 013469-7	97/856,282
		APPLICANT	
		BONNIE M. DAVIS	
		FILING DATE	GROUP
		June 18, 2001	1614
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)			
	AA	Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Psychiatry 1994; 151:390-396	
To follow	AB	http://clinicaltrials.gov/ct2/show/NCT00478205	
	AC	Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CRV, The cognitive benefits trial. Arch Neurol 2004; 61:252-256	
	AD	Hernandez CM, Goshart DA, Perlich V, Hohnadel EL, Davis LW, Middlemore ML, Warr SP, Waller II, Terry Jr AV 316-679-694	
	AE		
	AF		
	AG		
	AH		
	AI		
	AJ		
	AK		
	AL		
	AM		
	AN		
	AO		
EXAMINER /James Anderson/		DATE CONSIDERED 12/23/2008	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /JDA/